Skip to main content
. Author manuscript; available in PMC: 2016 Mar 18.
Published in final edited form as: Leuk Lymphoma. 2015 Oct 12;57(3):666–675. doi: 10.3109/10428194.2015.1071488

Figure 2.

Figure 2

Non-relapse mortality and relapse by route of busulfan administration. Intravenous (i.v.) busulfan is associated with a slightly increased risk of non-relapse mortality [i.v. busulfan subdistribution hazard ratio 2.58 (95% CI 1.02, 6.5), p = 0.045]. No statistically significant difference in relapse was noted by route of busulfan administration [i.v. busulfan subdistribution hazard ratio 0.63 (95% CI 0.29, 1.4), p = 0.258].